Progress against cardiovascular disease appears to have stalled, particularly with respect to measures such as premature heart disease mortality. Indeed, in recent years, such measures tell a story of momentum gained, then lost. So, in addition to doubling down on existing treatments, we need new ones. As this issue of GEN reports, new treatments—gene therapies, antibody fragments, and microRNA drug products—promise to restore medicine’s momentum against cardiovascular disease. In addition, this issue of GEN makes the case that in other fields—namely, next-generation sequencing, AAV vector design and manufacturing, and AI-driven bioprocessing—momentum-building projects continue apace. Finally, this issue of GEN presents our latest A-List: Top 10 Contract Development and Manufacturing Organizations. Besides ranking the leading CDMOs by revenue, we highlight recent announcements that show how CDMOs are exploring new product categories, building end-to-end service offerings, and cultivating more lasting relationships with clients.